BRAF and melanoma: According to the result from the phase III METRIC trial, trametinib single-agent treatment obtained an ORR of 22% and a median PFS of 4.8 months,406 which was not as ideal as that of BRAF-targeted therapy in melanoma harboring BRAF mutation.